Jeremy Vernon Elwes

The Foundation for Liver Research, founded in 1974, conducts research on liver diseases and aims to use multi-omic biological data for diagnostics, management stratification, and therapeutic design. The non-profit company is based in London, UK. The British company's research includes susceptibility to bacterial infection in liver failure patients, mechanisms of neutrophil dysfunction, and hydrogen sulphide as a novel therapy. The company also focuses on in silico models and primary liver cancer.

The Foundation for Liver Research, founded in 1974, conducts research on liver diseases and aims to use multi-omic biological data for diagnostics, management stratification, and therapeutic design. The non-profit company is based in London, UK. The British company's research includes susceptibility to bacterial infection in liver failure patients, mechanisms of neutrophil dysfunction, and hydrogen sulphide as a novel therapy. The company also focuses on in silico models and primary liver cancer.

The Foundation for Liver Research, founded in 1974, conducts research on liver diseases and aims to use multi-omic biological data for diagnostics, management stratification, and therapeutic design. The non-profit company is based in London, UK. The British company's research includes susceptibility to bacterial infection in liver failure patients, mechanisms of neutrophil dysfunction, and hydrogen sulphide as a novel therapy. The company also focuses on in silico models and primary liver cancer.

The Foundation for Liver Research, founded in 1974, conducts research on liver diseases and aims to use multi-omic biological data for diagnostics, management stratification, and therapeutic design. The non-profit company is based in London, UK. The British company's research includes susceptibility to bacterial infection in liver failure patients, mechanisms of neutrophil dysfunction, and hydrogen sulphide as a novel therapy. The company also focuses on in silico models and primary liver cancer.